Search clinical trials for: AXA1125

Total 7 results

Axcella Health, Inc

Completed

Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD

United States
Axcella Health, Inc

Recruiting

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Non Alcoholic Steatohepatitis (NASH)

United States, Canada, United Kingdom, Australia, France, Poland, Puerto Rico
Axcella Health, Inc

Completed

Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection

Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

United Kingdom
CoMentis
Alpharmagen, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects

Schizophrenia

United States
Axcella Health, Inc

Completed

Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency

Hepatic Insufficiency

United States
CoMentis
Alpharmagen, Inc.

Suspended

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

Schizophrenia

United States
Axcella Health, Inc

Terminated

Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy (EMMPOWER)

Hepatic Encephalopathy

Spain, United States, Canada, Italy, Hungary, Poland, United Kingdom

3

Subscribe